After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

Medtronic received Food and Drug Administration approval for the BrainSense Adaptive deep brain stimulation (DBS) device for ...

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...

(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.

T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...

The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available ...

For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

Medtronic's FDA-approved BrainSense Adaptive DBS system revolutionizes Parkinson's therapy with real-time adjustments for ...

The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...